Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hansoh Pharmaceutical Group CoHNSPF 94 3-Year EBITDA Growth Rate is 26.70% as of Dec. 2025, which is 82% above its 10-year median of 14.70. GuruFocus rates HNSPF with a GF Score™ of 94/100 and a GF Value™ of $3.76 (Modestly Overvalued). Among 807 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks better than 75.46% on this metric.
During the past 12 months, Hansoh Pharmaceutical Group Co's average EBITDA Per Share Growth Rate was 30.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 26.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 13.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hansoh Pharmaceutical Group Co was 26.70% per year. The lowest was -1.00% per year. And the median was 14.70% per year.
Hansoh Pharmaceutical Group Co (OTCPK:HNSPF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Hansoh Pharmaceutical Group Co 3-Year EBITDA Growth Rate Related Terms
HNSPF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's 3-Year EBITDA Growth Rate falls into.
Hansoh Pharmaceutical Group Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 26.70% mean?
Hansoh Pharmaceutical Group Co (HNSPF) has a 3-Year EBITDA Growth Rate of 26.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hansoh Pharmaceutical Group Co and its competitors. This is 82% above median its historical median of 14.70. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #198 out of 807 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is Hansoh Pharmaceutical Group Co's 3-Year EBITDA Growth Rate too high?
Hansoh Pharmaceutical Group Co's current 3-Year EBITDA Growth Rate of 26.70% is 82% above median its 10-year median of 14.70. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Hansoh Pharmaceutical Group Co's value of 26.70% is 200% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #198 out of 807 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #198 out of 807 companies for 3-Year EBITDA Growth Rate. This places Hansoh Pharmaceutical Group Co in the top 25% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Hansoh Pharmaceutical Group Co's value of 26.70% is 200% above this benchmark. While the company's 10-year median is 14.70 vs. the industry median of 8.90, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 807 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current 3-Year EBITDA Growth Rate of 26.70% is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current 3-Year EBITDA Growth Rate is 26.70%, which is 82% above median its own 10-year median of 14.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.76, compared to a current price of $4.61 — trading 22.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 26.70%, which is 82% above median its 10-year median of 14.70 and 200% above the Drug Manufacturers industry median of 8.90. Hansoh Pharmaceutical Group Co's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current 3-Year EBITDA Growth Rate is 26.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $4.61 is trading 22.6% above its estimated GF Value™ of $3.76.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for HNSPF:
3-Year EBITDA Growth Rate: 26.70% (82% above median its 10-year median of 14.70)
GF Value™: $3.76 vs. price of $4.61 (22.6% above fair value)
Industry Position: 200% above the Drug Manufacturers median (#198 of 807)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
94GF Score
Get the complete analysis for HNSPF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
